Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A

Wolfhart Kreuz; Joan C. Gill; Chantal Rothschild; Marilyn J. Manco-Johnson; Jeanne M. Lusher; Elke Kellermann; Eduard Gorina; Peter J. Larson; and the International Kogenate-FS Study Group

doi:10.1160/TH03-10-0643

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 93(03): 457-467
DOI: 10.1160/TH03-10-0643

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A

Results of an international clinical investigation

Authors

Wolfhart Kreuz

⁷The Center of Pediatrics III, Department of Hematology, Oncology and Hemostaseology, Johann Wolfgang Goethe-University Hospital, Frankfurt am Main, Germany
Joan C. Gill

¹Blood Center of Southeastern Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Chantal Rothschild

²Hôpital Necker, Centre de l'Hemophilie F. Josso, Paris, France
Marilyn J. Manco-Johnson

³Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado, USA
Jeanne M. Lusher

⁴Children's Hospital of Michigan, Detroit, Michigan, USA
Elke Kellermann

⁵Bayer Vital GmbH Biological Products, Leverkusen, Germany
Eduard Gorina

⁶Bayer Health Care, Biological Products Division, Research Triangle Park, North Carolina, USA
Peter J. Larson

⁶Bayer Health Care, Biological Products Division, Research Triangle Park, North Carolina, USA

and the International Kogenate-FS Study Group

Abstract

Summary

The safety and efficacy of a full-length sucrose-formulated recombinant factor VIII product (rFVIII-FS; Kogenate^FS; Kogenate^ Bayer) was evaluated in previously untreated (PUPs) and minimally treated (MTP) patients with severe haemophilia A (FVIII < 2%). Patients (37 PUPs; 24 MTPs) aged 0.1–25.7 months were treated with rFVIII-FS for a cumulative of 9,141 exposure days (EDs), median 114 EDs (range 4–478), on prophylactic or on-demand therapy. Eighty-nine percent of all treated bleeding episodes were successfully treated with 1 (74%) or 2 (15%) infusions. Clinical response to first infusion for each bleeding episode was rated as ‘excellent’ in 58%, or ‘good’ in 33%, of all cases. Recombinant FVIII-FS was used in 27 surgical procedures, mainly catheter implantations, which were all conducted without bleeding complications. FVIII recovery mean values (~2%/kg/ IU) were as expected for any licensed FVIII concentrate. FVIII neutralizing antibody formation was 15% (9/60). Aside from inhibitor formation, three adverse events were rated as ‘at least possibly drug-related’ for a total drug-related adverse event rate of 0.14%. No viral seroconversions were observed. Overall, excellent safety and efficacy were demonstrated with rFVIII-FS for therapy of young children with severe haemophilia A.

Keywords

Haemophilia A - FVIII inhibitor - pediatric - PUPs

Full Text

References

References
1 Giles AR, Rivard GE, Teitel J. et al. Surveillance for factor VIII inhibitor development in the Canadian Haemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-48.
2 Aygören-Pürsün E, Scharrer I. the German Kogenate Study Group. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with haemophilia A. Thromb Haemost 1997; 78: 1352-6
3 Seremetis S, Lusher JM, Abildgaard CF. et al. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 1999; 5: 9-16.
4 Lusher JM, Arkin S, Abildgaard CF. et al. Kogenate treatment of previously untreated patients (PUPs) with haemophilia A: update of safety, efficacy, and inhibitor development after 7 study years. Blood 1996; 88 (10) 442 A (Abstract 1755)
5 Medical and Scientific Advisory Council (MASAC) Recommendation regarding the use of recombinant factor VIII in the treatment of haemophilia A. National Haemophilia Foundation 1995; Medical Bulletin # 232 (Chapter Advisory # 234)
6 Boedeker BG. Production processes of licensed recombinant factor VIII preparations. Semin Thromb Hemost 2001; 27: 385-94.
7 Brackmann HH, Abshire T, Scharrer I. et al. Safety and efficacy of a sucrose-formulated recombinant factor VIII (rFVIII-SF) during home treatment of patients with severe haemophilia A. Haemophilia 1998; 4: 190
8 Abshire T, Brackmann H-H, Scharrer I. et al. Sucrose- formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of haemophilia A in home therapy: results of a multicenter, international, clinical investigation. Thromb Haemost 2000; 83: 811-16.
9 Scharrer I, Brackmann H-H, Sultan Y. et al. Efficacy of a sucrose formulated recombinant factor VIII (rFVIII-SF) used for 22 surgical procedures in patients suffering from severe haemophilia A. Haemophilia 2000; 6: 614-18.
10 The European Agency for the Evaluation of Medicinal Products Note for guidance to assess efficacy and safety of human plasma derived factor VIII: C and factor IX: C products in clinical trials in haemophiliacs before and after authorization. 1996; CPMP/198/95 Final
11 White GC, DiMichele DM, Mertens K. et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new Factor VIII and Factor IX concentrates. Thromb Haemost 1999; 81: 462
12 The European Agency for the Evaluation of Medicinal Products Note for guidance on the clinical investigation of recombinant factor VIII and IX products. 2000 CPMP/BPWP/1561/99
13 Verbruggen B, Novakova I, Wessels H. et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
14 Larson PJ, Zhang C, Gorina E. et al. IgG formation to mammalian proteins in haemophilia patients following treatment with a new recombinant human factor VIII. Blood 2002; 100 (11 (Part 2 of 2 Parts)) 110b
15 Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
16 Bray GL, Gomperts ED, Courter S. et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with haemophilia A. Blood 1994; 83: 2428-35.
17 Hay CR. Factor VIII inhibitors in mild and moderate- severity haemophilia A. Haemophilia 1998; 4: 558-63.
18 Ohta H, Takahashi I, Kojima T. et al. Histocompatibility antigens and alleles in Japanese haemophilia A patients with or without factor VIII antibodies. Tissue Antigens 1999; 54: 91-7.
19 Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in haemophilia A. Haematologica 2000; 85 (Suppl. 10) 7-13. discussion 13–4
20 Astermark J, Berntorp E, White GC. et al. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in haemophilia patients. Haemophilia 2001; 7: 267-72.
21 Schwaab R, Brackmann HH, Meyer C. et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
22 Millar DS, Steinbrecher RA, Wieland K. et al. The molecular genetic analysis of haemophilia A; characterization of six partial deletions in the factor VIII gene. Hum Genet 1990; 86: 219-27.
23 Lorenzo I J, Lopez A, Altisent C. et al. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-3.
24 Van Der Bom JG, Mauser-Bunschoten EP, Fischer K. et al. Age at first treatment and immune tolerance to factor VIII in severe haemophilia. Thromb Haemost 2003; 89: 475-9.
25 Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
26 Lusher JM. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost 2002; 28: 273-6.
27 Lusher J, Abildgaard C, Arkin S. et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with haemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574-83.
28 Yoshioka A, Shima M, Fakutake K. et al. and the KOGENATE® FS Study Group. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a longterm, multi-centre clinical study in Japan. Haemophilia 2001; 7: 242-49.
29 Larson P, Zhang C, Gorina E. et al. IgG formation to mammalian proteins in haemophilia A patients following treatment with a new recombinant human factor VIII. J Thromb Haemost 2004; 2: 1011-12.
30 Ingerslev J, Christiansen K, Ravn HB. et al. Antibodies to heterologous proteins in haemophilia A patients receiving recombinant factor VIII (Recombinate). Thromb Haemost 2002; 87: 626-34.
31 Yoshioka A, Fukutake K, Takamatsu J. et al. and the Kogenate Post-Marketing Surveillance Study Group. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously untreated patients with haemophilia A. Int J Hematol 2003; 78: 467-74.
32 Suiter TM. First and next generation native rFVIII in the treatment of haemophilia A. What has been achieved? Can patients be switched safely?. Semin Thromb Hemost 2002; 28: 277-84.